Evidence map›Paper›PMID 42388121›Full record

ArticleNeurocase2026

Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab.

Nicholas U Schwartz, Connor D Dietz, Zoe Lin, Gautam Tammewar, Nhat Bui, Renaud La Joie, Yingbing Wang, Anirudh Sreekrishnan, Dror Suhami, Lawren VandeVrede and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurocase, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicholas U SchwartzEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1040-7819
Connor D DietzEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Zoe LinEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Gautam TammewarEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Nhat BuiEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Renaud La JoieEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Yingbing WangDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Anirudh SreekrishnanDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Dror SuhamiDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Lawren VandeVredeEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Peter A LjubenkovEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3348-9215
Julio C RojasEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

Funding

Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP)R01AG085029 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L., LITVAN, IRENE · 2024 to 2025
$30.3M
Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasT32AG023481 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRUCE L MILLER, HOWARD J ROSEN · 2005 to 2026
$7.4M
Proteomics for fluid biomarker discovery in frontotemporal dementiaK23AG059888 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROJAS-MARTINEZ, JULIO CESAR · 2019 to 2023
$995k
NIA NIH HHS K23 AG059888NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG085029NIA NIH HHS T32 AG023481
6 · The paper itself

Abstract

Amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) and with hemorrhage (ARIA-H) are common adverse effects of amyloid-targeting therapies (ATT), characterized on MRI by T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities and susceptibility-sensitive hypointensities, respectively. ARIA resulting from ATT is not commonly associated with reduced diffusion or acute infarcts. In this case series, we describe three patients with mild cognitive impairment due to Alzheimer's disease (AD) - a 75-year-old woman, a 74-year-old woman, and an 80-year-old man (

Indexed as

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedBrainBrain EdemaCognitive DysfunctionAgedAged, 80 and overDiffusion Magnetic Resonance ImagingFemaleHumansMaleAntibodies, Monoclonal, Humanizeddonanemabamyloid-targeting therapyARIAdonanemabDWIinfarctstroke

Identifiers

PMID42388121
PMCPMC13431785

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.